Wealth Enhancement Advisory Services
AGIO icon

Wealth Enhancement Advisory Services’s Agios Pharmaceuticals AGIO Stock Holding History

Wealth Enhancement Advisory Services’s Portfolio AGIO Stock Details AGIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$740K Buy
+17,959
New +$545K ﹤0.01% 2325

Other funds holding AGIO

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
MFG
Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
CHC
City Holding Co Charleston, West Virginia $884M AUM 27.52% 1-Year Est. Return

Wealth Enhancement Advisory Services's AGIO Position: Q2 2026 in Review

Wealth Enhancement Advisory Services opened a new position in Agios Pharmaceuticals (AGIO) in Q2 2026: 17,959 shares worth $740K. The stake represents ﹤0.01% of the portfolio and ranks #2325 among its holdings.

21 funds tracked by Wall St. Rank hold AGIO as of Q2 2026.

  • Wealth Enhancement Advisory Services held 17,959 shares of Agios Pharmaceuticals worth $740K as of Q2 2026.
  • Agios Pharmaceuticals was a new Wealth Enhancement Advisory Services position in Q2 2026.
  • Agios Pharmaceuticals made up ﹤0.01% of Wealth Enhancement Advisory Services's portfolio in Q2 2026, its #2325 holding.
  • 21 funds tracked by Wall St. Rank held Agios Pharmaceuticals as of Q2 2026.

Based on Wealth Enhancement Advisory Services's 13F filing for Q2 2026, filed 15 Jul 2026.